Candida auris biofilm: a review on model to mechanism conservation
Abstract
Introduction Candida auris is included in the fungal infection category ‘critical’ by WHO because of associated high drug tolerance and spread at an alarming rate which if remains untouched may result in serious outbreaks. Since its discovery in 2009, several assiduous efforts by mycologists across the world have deciphered its biology including growth physiology, drug tolerance, biofilm formation, etc. The differential response of various strains from different clades poses a hurdle in drawing a final conclusion.Areas covered This review provides brief insights into the understanding of C. auris biofilm. It includes information on various models developed to understand the biofilms and conservation of different signaling pathways. Significant development has been made in the recent past with the generation of relevant in vivo and ex vivo models. The role of signaling pathways in the development of biofilm is largely unknown.Expert opinion The selection of an appropriate model system is a must for the accuracy and reproducibility of results. The conservation of major signaling pathways in C. auris with respect to C. albicans and S. cerevisiae highlights that initial inputs acquired from orthologs will be valuable in getting insights into the mechanism of biofilm formation and associated pathogenesis.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
C. auris biofilms are distinct from C. albicans biofilms and usually consist of yeast cells with a low amount of extracellular matrix.
“C. auris biofilms are distinct from that of C. albicans and usually consist of yeast cells with a low amount of extracellular matrix (12).”
From Ume6-dependent pathways of morphogenesis and biofilm formation in <i>Candida auris</i> (2024) · cites this paper as [12]
Cites
Candida auris: Epidemiology, biology, antifungal resistance, and virulence
Du, H., Bing, J., Hu, T., Ennis, C. L., Nobile, C. J., & Huang, G. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1008921 · Cited by 609 · see citing works
Rajendran, R., Sherry, L., Nile, C. J., Sherriff, A., Johnson, E. M., Hanson, M. F., Williams, C., Munro, C. A., Jones, B. J., & Ramage, G. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.09.018 · Cited by 228 · see citing works
Kean, R., Delaney, C., Sherry, L., Borman, A., Johnson, E. M., Richardson, M. D., Rautemaa-Richardson, R., Williams, C., & Ramage, G. (2018) · mSphere · doi:10.1128/msphere.00334-18 · Cited by 220 · see citing works
Nett, J. E., Sanchez, H., Cain, M. T., Ross, K. M., & Andes, D. R. (2011) · Eukaryotic Cell · doi:10.1128/ec.05126-11 · Cited by 168 · see citing works
Candida auris Forms High-Burden Biofilms in Skin Niche Conditions and on Porcine Skin
Horton, M. V., Johnson, C. J., Kernien, J. F., Patel, T. D., Lam, B. C., Cheong, J. Z. A., Meudt, J. J., Shanmuganayagam, D., Kalan, L. R., & Nett, J. E. (2020) · mSphere · doi:10.1128/msphere.00910-19 · Cited by 159 · cited 2× · see citing works
“albicans, on the other hand, revealed no fungal development [8].”
BackgroundConserved Role for Biofilm Matrix Polysaccharides in <i>Candida auris</i> Drug Resistance
Dominguez, E. G., Zarnowski, R., Choy, H. L., Zhao, M., Sanchez, H., Nett, J. E., & Andes, D. R. (2019) · mSphere · doi:10.1128/mspheredirect.00680-18 · Cited by 132 · see citing works
Candida auris Infection and Biofilm Formation: Going Beyond the Surface
Horton, M. V., & Nett, J. E. (2020) · Current Clinical Microbiology Reports · doi:10.1007/s40588-020-00143-7 · Cited by 132 · see citing works
Role of matrix β-1,3 glucan in antifungal resistance of non-albicans Candida biofilms
Mitchell, K. F., Taff, H. T., Cuevas, M. A., Reinicke, E. L., Sanchez, H., & Andes, D. R. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02378-12 · Cited by 104 · see citing works
Roles of Calcineurin and Crz1 in Antifungal Susceptibility and Virulence of <i>Candida glabrata</i>
Miyazaki, T., Yamauchi, S., Inamine, T., Nagayoshi, Y., Saijo, T., Izumikawa, K., Seki, M., Kakeya, H., Yamamoto, Y., Yanagihara, K., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01364-09 · Cited by 88 · see citing works
Vila, T., Montelongo-Jauregui, D., Ahmed, H., Puthran, T., Sultan, A. S., & Jabra-Rizk, M. A. (2020) · mSphere · doi:10.1128/msphere.00760-20 · Cited by 58 · see citing works
Calcium-calcineurin signaling pathway in Candida albicans: A potential drug target
Li, W., Shrivastava, M., Lu, H., & Jiang, Y. (2021) · Microbiological Research · doi:10.1016/j.micres.2021.126786 · Cited by 47 · see citing works
Kim, S. H., Iyer, K. R., Pardeshi, L., Muñoz, J. F., Robbins, N., Cuomo, C. A., Wong, K. H., & Cowen, L. E. (2019) · mBio · doi:10.1128/mbio.00346-19 · Cited by 28 · cited 1× · see citing works
“auris from yeast to filamentous form [84].”
Flagged first, then by citations
Cited by
Sorted by citations
Ume6-dependent pathways of morphogenesis and biofilm formation in <i>Candida auris</i>
Louvet, M., Li, J., Brandalise, D., Bachmann, D., Sala de Oyanguren, F., Labes, D., Jacquier, N., Genoud, C., Mucciolo, A., Coste, A. T., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.01531-24 · Cited by 20 · see citing works
- Authors
- Khari, A., Biswas, B., Gangwar, G., Thakur, A., & Puria, R.
- Affiliations
- Gautam Buddha University (IN)
- Regional Centre for Biotechnology (IN)
- Corresponding author
- Puria, Rekha
- ORCID
- Puria, Rekha
- Venue
- Expert Review of Anti-infective Therapy
- Publisher
- Informa UK Limited
- Published
- 2023-02-16
- Volume
- 21
- Issue
- 3
- Pages
- 295-308
- ISSN
- 1478-7210 (ISSN-L)
- 1744-8336
- OpenAlex
- W4319657018
- Cited by
- 18
- References
- 12
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 5 · 2023: 4
- FWCI
- 0.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Review of Anti-infective Therapy (publishedVersion)
- PubMed (publishedVersion)
- Funders
- SERB (CRG/2021/003585)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bacterial biofilms and quorum sensing
- Keywords
- Candida auris, biofilm formation, signaling pathways, drug tolerance, pathogenesis, antifungal resistance
- MeSH terms
- Candida auris, Antifungal Agents, Candida, Candida albicans, Humans, Saccharomyces cerevisiae, Reproducibility of Results, Biofilms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
